Identification of a Poor-PrognosisBRAF-Mutant–Like Population of Patients With Colon Cancer

New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC).

(2017) E. Budinska et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

(2017) R. Kefford et al.   JOURNAL OF CLINICAL ONCOLOGY

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

(2010) J. R. Dry et al.   CANCER RESEARCH

The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status

(2010) A. M. Dahlin et al.   CLINICAL CANCER RESEARCH

Role of the Serrated Pathway in Colorectal Cancer Pathogenesis

(2010) Barbara Leggett et al.   GASTROENTEROLOGY

Update on the serrated pathway to colorectal carcinoma

(2010) Dale C. Snover   HUMAN PATHOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

(2010)   NATURE BIOTECHNOLOGY

Three DNA Methylation Epigenotypes in Human Colorectal Cancer

(2009) K. Yagi et al.   CLINICAL CANCER RESEARCH

Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer

(2009) J. Joshua Smith et al.   GASTROENTEROLOGY

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?

(2008) Sérgia Velho et al.   BMC CANCER

Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype

(2008) D. R. English et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer

(2008) A. J. French et al.   CLINICAL CANCER RESEARCH

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

(2008) S. Ogino et al.   GUT

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas

(2008) Caroline Kannengiesser et al.   Molecular Oncology

Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample

(2008) Katsuhiko Nosho et al.   PLoS One